Shots:

• The approval follows P-III ZOE-50 and ZOE-70 studies assessing Shingrix in 38-000 patients with shingles (herpes zoster) aged ≥ 50yrs.
• The P-III ZOE-50 and ZOE-70 studies demonstrated efficacy >90% in all age group and showed sustained efficacy over a follow period of 4yrs.
• Shingrix (IM) is a herpes zoster vaccine- administered in two doses and is a combination of an antigen- glycoprotein E- an adjuvant system- AS01B- currently available in the US- EU- Canada- Japan and Australia

Ref: GSK | Image: GSK